HighTower Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

HighTower Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,000	Closed	-$3.85K	–	3993
2023 Q4	$3.85K	Buy	+7,000	New	+$65.4K	﹤0.01%	3480
2023 Q3	–	Sell	-250	Closed	-$9.5K	–	3747
2023 Q2	$9.5K	Buy	+250	New	+$2.03K	﹤0.01%	3310
2022 Q1	–	Sell	-400	Closed	-$29K	–	3674
2021 Q4	$29K	Sell	400 -205,600	-100%	-$1.86M	﹤0.01%	3076
2021 Q3	$151K	Buy	+206,000	New	+$1.93M	﹤0.01%	2775
2021 Q2	–	Sell	-1,360	Closed	-$107K	–	3380
2021 Q1	$107K	Buy	1,360 +1,260	+1,260%	+$14.4K	﹤0.01%	2748
2020 Q4	$1K	Buy	+100	New	+$958	﹤0.01%	2586
2019 Q3	–	Sell	-2,500	Closed	-$1K	–	2539
2019 Q2	$1K	Buy	+2,500	New	+$30.1K	﹤0.01%	2369

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

HighTower Advisors's TEVA Position: Q2 2026 in Review

HighTower Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 8.2% in Q2 2026, selling an estimated $615K and leaving 205,600 shares worth $6.97M. The position accounts for 0.01% of the portfolio, ranked #1081.

HighTower Advisors first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.2M in Q1 2015. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

HighTower Advisors held 205,600 shares of Teva Pharmaceuticals worth $6.97M as of Q2 2026.
HighTower Advisors sold 18,467 Teva Pharmaceuticals shares in Q2 2026, an estimated $615K.
Teva Pharmaceuticals made up 0.01% of HighTower Advisors's portfolio in Q2 2026, its #1081 holding.
HighTower Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
HighTower Advisors's Teva Pharmaceuticals position peaked at $12.2M in Q1 2015.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.